This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Under $10 Set to Soar

Cornerstone Therapeutics

Another under-$10 stock in the biotechnology and drugs complex that looks ready to trigger a major breakout trade is Cornerstone Therapeutics (CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. This stock has been trending higher so far in 2012, with shares up over 25%.

This company just announced on Wednesday that the FDA has scheduled a review of the new drug application for Lixivaptan. The drug treats a condition in which the blood sodium levels of patients with heart failure are abnormally low. The FDA panel will meet to discuss Lixivaptan on Sept. 13.

If you take a look at the chart for Cornerstone Therapeutics, you'll notice that this stock has been uptrending strong for the past month and a half, with shares soaring from $4.88 to a recent high of $7.25 a share. During that sharp move higher, shares of Cornerstone Therapeutics have been making higher lows and higher highs, which is bullish technical price action. This stock also just triggered a major breakout trade once it cleared some key overhead resistance levels at $6.96 to $7.00 a share with monster volume. Volume for the last two trading sessions as registered 807,000 shares and 203,000 shares, which is well above its three-month average action of 64,970 shares. This move is now setting up CRTX to continue its run higher, possibly right into its FDA meeting on Sept. 13.

>>Hot Biotech Stocks Traded by Hedge Funds

Traders should now look for long-biased trades in CRTX if this stock can manage to sustain its breakout above $6.50 to $7.00 a share with strong upside volume flows. I would consider any upside volume day that registers near or above 64,970 shares as bullish. If we continue to see CRTX sustain that trend, then this stock has a great chance of re-testing and possibly taking out its next major overhead resistance levels at $8.50 to $9.20 a share.

If you like the setup for CRTX here, then one could look to buy this stock off any weakness and simply use a stop just under $6.50 a share, or possibly even around $6.20 if you want to give it more room to the downside. This stock could even pullback to $6 a share and still be well within its healthy uptrend, but I would prefer to see it hold above those key breakout levels of $6.50 to $7 a share.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ZLCS $9.04 -0.22%
CRTX $0.00 0.00%
PSTI $2.82 -0.70%
PACB $6.14 -1.00%
VRNG $0.68 -4.00%

Markets

DOW 18,009.31 -25.62 -0.14%
S&P 500 2,104.03 +3.63 0.17%
NASDAQ 5,019.7440 +25.1420 0.50%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs